Amylyx Pharmaceuticals vs Monopar Therapeutics
AMLX and MNPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and MNPR compare
Amylyx Pharmaceuticals is the larger company, worth 7.0 times as much as Monopar Therapeutics ($3.4B against $483M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | MNPR |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $483M |
| Share price | $30.29 | $72.00 |
| Change, 1 year | 146% | −12.8% |
| Change, 5 years | 182% | 206% |
| Beta (5Y) | 1.15 | 0.78 |
| Employees | 136 | 22 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 4.5× | 3.8× (better) |
| Profitability | ||
| Return on equity | −30.1% | −15.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.81 | 43.55 (better) |
| Altman Z-score | 60.09 | 90.53 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 92.7% |
| Held by insiders | 7.8% | – |
| Insider net buying, 12 months | −$17.2M | −$5.6M (better) |
| Short interest, % of float | 12.5% | – |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- MNPR stock overview
- MNPR income statement
- MNPR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.